This is easily demonstrated through the known significant clinical impact of the CIMP-high phenotype in colorectal cancer and the simultaneous presence of TP53 mutations and BRAFV600E mutations or, similarly, the G-CIMP subgroup of glioma tumours with concurrent IDH1 mutations [6, 7]. This evidence concerns the gene IDH1 and glioma.